Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
AVBP 
ArriVent BioPharma, Inc. Common Stock (AVBP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/17/2025: AVBP (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $39.56
1 Year Target Price $39.56
| 6 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -16.11% | Avg. Invested days 23 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 791.50M USD | Price to earnings Ratio - | 1Y Target Price 39.56 |
Price to earnings Ratio - | 1Y Target Price 39.56 | ||
Volume (30-day avg) 7 | Beta - | 52 Weeks Range 15.47 - 36.37 | Updated Date 10/18/2025 |
52 Weeks Range 15.47 - 36.37 | Updated Date 10/18/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -23.41% | Return on Equity (TTM) -50.06% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 528324215 | Price to Sales(TTM) - |
Enterprise Value 528324215 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 40568944 | Shares Floating 19409400 |
Shares Outstanding 40568944 | Shares Floating 19409400 | ||
Percent Insiders 8.24 | Percent Institutions 88.67 |
Upturn AI SWOT
ArriVent BioPharma, Inc. Common Stock
Company Overview
History and Background
ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines for patients with cancer. Founded in 2021, it aims to address unmet medical needs with a focus on Greater China and the global market.
Core Business Areas
- Drug Development: Focused on the clinical development of cancer therapies acquired from other companies, primarily in Greater China.
- Licensing and Partnerships: Securing licenses for promising drug candidates and establishing strategic partnerships for development and commercialization.
Leadership and Structure
The leadership team comprises experienced professionals in drug development and commercialization. The organizational structure is designed to facilitate efficient clinical trials and regulatory submissions.
Top Products and Market Share
Key Offerings
- Furmonertinib: A novel EGFR tyrosine kinase inhibitor (TKI) for non-small cell lung cancer (NSCLC) with brain metastases. Market share data is not yet available. Competitors: Tagrisso (osimertinib), other EGFR TKIs.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, regulatory hurdles, and intense competition. The oncology market is particularly lucrative but also crowded.
Positioning
ArriVent BioPharma is positioning itself as a specialist in oncology, focusing on targeted therapies with a China-centric approach.
Total Addressable Market (TAM)
The global oncology market is estimated at hundreds of billions of dollars. ArriVent targets specific niches within this market. Positioning includes focusing on regions, like China, to build share.
Upturn SWOT Analysis
Strengths
- Experienced management team
- Strategic focus on China
- Promising drug candidate (furmonertinib)
- Partnerships with established pharmaceutical companies
Weaknesses
- Limited operating history
- Reliance on single drug candidate
- High cash burn rate typical of biotech
- Dependence on licensed technologies
Opportunities
- Expanding into new oncology indications
- Securing additional licensing agreements
- Growing demand for targeted therapies in China
- Potential for strategic acquisitions
Threats
- Clinical trial failures
- Regulatory delays
- Competition from established pharmaceutical companies
- Intellectual property disputes
Competitors and Market Share
Key Competitors
- AZN
- MRK
- BMY
- LLY
Competitive Landscape
ArriVent faces intense competition from established pharmaceutical companies with greater resources and existing market presence. Its competitive advantage lies in its China-centric strategy and focus on targeted therapies.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited due to the company's recent inception.
Future Projections: Future growth is dependent on the successful development and commercialization of furmonertinib and other pipeline candidates. Analyst estimates vary widely based on clinical trial outcomes.
Recent Initiatives: Focus on accelerating clinical trials for furmonertinib and expanding its pipeline through licensing and partnerships.
Summary
ArriVent BioPharma is a young, clinical-stage company with a promising lead drug candidate, furmonertinib. Its China-centric strategy offers potential advantages. However, it faces significant risks related to clinical trial outcomes, regulatory approvals, and competition. Funding and partnerships will be critical for long-term success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Company Website
- Analyst Reports
- Industry Databases
Disclaimers:
This analysis is based on publicly available information and should not be considered financial advice. The information provided is subject to change without notice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About ArriVent BioPharma, Inc. Common Stock
Exchange NASDAQ | Headquaters Newtown Square, PA, United States | ||
IPO Launch date 2024-01-26 | Co-Founder, Chairman, President & CEO Dr. Zhengbin Yao Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 52 | Website https://arrivent.com |
Full time employees 52 | Website https://arrivent.com | ||
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.